Delcath Systems, Inc., an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced that the company will present at Access to Giving Virtual Conference.
NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that the company will present at Access to Giving Virtual Conference. The presentation will be given by Delcath’s Chief Executive Officer, Gerard Michel. The conference is free to all registrants.
Registration Details
Date: Tuesday, July 13, 2021
Time: 3 p.m. ET
Link: https://access-to-giving.events.issuerdirect.com/signup
To learn more about the event or to schedule a one-on-one meeting with Delcath’s management, please visit https://www.accesstogiving.com/ or email james@haydenir.com.
About Access to Giving Virtual Conference
Access to Giving is a first-of-its-kind virtual investor conference where companies will have the opportunity to present their story and conduct 1x1 meetings with qualified investors, for charity. Investors will make donations to purchase a block of meetings to meet with companies.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.
Contact
Delcath Investor Relations
Email: investorrelations@delcath.com
Hayden IR
James Carbonara
(646)-755-7412
james@haydenir.com
